Cell culture-derived influenza vaccines in the severe 2017–2018 epidemic season: a step towards improved influenza vaccine effectiveness

npj Vaccines

Volumn 3, Issue 1, 2018, Pages

  Barr, Ian G ^a   Donis, Ruben O ^b   Katz, Jacqueline M ^c   McCauley, John W ^d   Odagiri, Takato ^e   Trusheim, Heidi ^f   Tsai, Theodore F ^g   Wentworth, David E ^c  

^a PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^b Biomedical Advanced Research and Development Authority   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^f IDT Biologika GmbH   (Germany)

^g Takeda Vaccines Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054588464     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/s41541-018-0079-z     Document Type: Review

References (53)

1. Garten, R. et al. Update: influenza activity in the United States during the 2017–18 season and composition of the 2018-19 influenza vaccine. Morb. Mortal. Wkly. Rep. 67, 634–642 (2018)
2. Centers for Disease Control and Prevention. Weekly U.S. influenza surveillance report: FluView. https://www.cdc.gov/flu/weekly/index.htm (20 April 2018)
3. Schuchat, A. Transcript for CDC update on flu activity. https://www.cdc.gov/media/releases/2018/t0202-flu-update-activity.html (2 February 2018)
4. European Centre for Disease Prevention and Control. Weekly influenza update, week 15, April 2018. https://www.ecdc.europa.eu/en/publications-data/weekly-influenza-update-week-15-april-2018 (20 April 2018)
5. McCauley, J. M., Daniels, R. & Lin, Y. Report prepared for the WHO Annual Consultation on the Composition of Influenza Vaccine for the Northern Hemisphere 2018-2019 (WHO Collaborating Centre for Reference & Research on Influenza, London, UK, 2018)
6. Australian Influenza Surveillance Report No 10 – week ending 29 September 2017. (Australian Government, Department of Health, Canberra, 2017)
7. Centers for Disease Control and Prevention. Estimated influenza illnesses, medical visits, hospitalizations, and deaths averted by vaccination in the United States. https://www.cdc.gov/flu/about/disease/2015-16.htm (4 May 2018)
8. Vestergaard, L. S. et al. Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. Euro. Surveill. 22(14):pii=30506 (2017)
9. Sullivan, S. G., Feng, S. & Cowling, B. J. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert. Rev. Vaccin. 13, 1571–1591 (2014)
10. Belongia, E. A. et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect. Dis. 16, 942–951 (2016)
11. Flannery, B. et al. Interim estimates of 2017–18 seasonal influenza vaccine effectiveness - United States, February 2018. Morb. Mortal. Wkly. Rep. 67, 180–185 (2018)
12. Skowronski, D. M. et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Euro. Surveill. 23(5):pii=18-00035 (2018)
13. Rondy, M. et al. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Euro. Surveill. 239 (21):pii=18-00086 (2018)
14. Sullivan, S. G. et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro. Surveill. 22(43):pii=17-00707 (2017)
15. Flannery, B. et al. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. J. Infect. Dis. 214, 1010–1019 (2016)
16. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018-2019 northern hemisphere influenza season. Wkly. Epidemiol. Rec. 93, 133–141 (2018)
17. Budd, A. P. et al. Update: influenza activity - United States, October 1, 2017-February 3, 2018. Morb. Mortal. Wkly. Rep. 67, 169–179 (2018)
18. Gottlieb, S. US House of Representatives, Testimony for the Committee on Energy and Commerce, Subcommittee on Oversight and Investigations: examining U.S. public health preparedness for and response efforts to seasonal influenza. Washington, DC. http://docs.house.gov/meetings/IF/IF02/20180308/106967/HHRG-115-IF02-Transcript-20180308.pdf (2018)
19. Skowronski, D. M. et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE 9, e92153 (2014)
20. Robertson, J. S. Clinical influenza virus and the embryonated hen’s egg. Rev. Med. Virol. 3, 97–106 (1993)
21. Schild, G. C., Oxford, J. S., de Jong, J. C. & Webster, R. G. Evidence for host-cell selection of influenza virus antigenic variants. Nature 303, 706–709 (1983)
22. Katz, J. M. & Webster, R. G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 160, 191–198 (1989)
23. Rappuoli, R. et al. Public health. Rethink. Influenza Sci. 326, 50 (2009)
24. Hampson, A. et al. Improving the selection and development of influenza vaccine viruses - report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015. Vaccine 35, 1104–1109 (2017)
25. Frey, S. et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin. Infect. Dis. 51, 997–1004 (2010)
26. Seqirus. Seqirus Announces Next Major Advancement in Cell-Based Influenza Vaccine Technology(Holly Springs, NC, 2017.)
27. Food and Drug Administration. Food and Drug Administration Letter of Approval: Biologics License Application Supplement for Influenza Vaccine (Flucelvax®) to include the use of MDCK cell isolated candidate vaccine virus strains obtained from CDC and the Victorian Infectious Diseases Reference Laboratory (Australia). (ed. CBER/FDA) Washington, D. C.: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM522280.pdf (2016)
28. Centers for Disease Control and Prevention. Cell-based flu vaccines. https://www.cdc.gov/flu/protect/vaccine/cell-based.htm(2018)
29. Lu, Y., Izurieta, H. S. & Forshee, R. Relative effectiveness of cell-cultured versus egg-based influenza vaccines, 2017–18. Advisory Committee on Immunization Practices (June 20, 2018) Y. Lu et al.; FDA/CBER (Centers for Disease Control and Prevention, Atlanta, 2018)
30. Lurie, N. HHS efforts to improve the influenza vaccine production enterprise. March 8, 2011, Briefing to The President’s Council of Advisors on Science and Technology: https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/pcast-lurie-march.pdf (2011)
31. Onions, D., Egan, W., Jarrett, R., Novicki, D. & Gregersen, J. P. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 38, 544–551 (2010)
32. Minor, P. D. et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 27, 2907–2913 (2009)
33. Donis, R. O. et al. Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing. Vaccine 32, 6583–6590 (2014)
34. Roth, B., Mohr, H., Enders, M., Garten, W. & Gregersen, J. P. Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses. Vaccine 30, 517–522 (2012)
35. Pyhala, R., Pyhala, L., Valle, M. & Aho, K. Egg-grown and tissue-culture-grown variants of influenza A (H3N2) virus with special attention to their use as antigens in seroepidemiology. Epidemiol. Infect. 99, 745–753 (1987)
36. Chen, Z., Zhou, H. & Jin, H. The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine 28, 4079–4085 (2010)
37. Saito, T. et al. Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation. J. Med. Virol. 74, 336–343 (2004)
38. Furuya, Y. et al. Effect of inactivation method on the cross-protective immunity induced by whole ‘killed’ influenza A viruses and commercial vaccine preparations. J. Gen. Virol. 91, 1450–1460 (2010)
39. Kon, T. C. et al. Influenza vaccine manufacturing: effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes. PLoS ONE 11, e0150700 (2016)
40. She, Y. M., Cheng, K., Farnsworth, A., Li, X. & Cyr, T. D. Surface modifications of influenza proteins upon virus inactivation by beta-propiolactone. Proteomics 13, 3537–3547 (2013)
41. Dunkle, L. M. et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N. Engl. J. Med. 376, 2427–2436 (2017)
42. World Health Organization. Evaluation of Influenza Vaccine Effectiveness: A Guide to the Design and Interpretation of Observational Studies. (World Health Organization, Department of Immunization, Vaccines and Biologicals: Geneva, 2017.)
43. Food and Drug Administration. Influenza Virus Vaccine for the 2017–2018 Season: Cumulative 2017/2018 Season Lot Release Status. Washington, DC. https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm567865.htm (2017)
44. Hughes, M. et al. Modeling projected impact of increased vaccination effectiveness and coverage on influenza burden - United States, 2016–2017 (ed. CDC) 67th Annual Epidemic Intelligence Service (EIS) Conference (CDC, Atlanta, GA, USA, 2018)
45. Vesikari, T. et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365, 1406–1416 (2011)
46. Izurieta, H. S. et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect. Dis. 15, 293–300 (2015)
47. Shay, D.K. et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US medicare beneficiaries in preventing postinfluenza deaths during 2012–2013 and 2013–2014. J. Infect. Dis. 215, 510–517 (2017)
48. Landry, N. et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 5, e15559 (2010)
49. US. Public Law 109–417. 109th Congress: Pandemic and All-Hazards Preparedness Act. Washington, DC. https://www.gpo.gov/fdsys/pkg/PLAW-109publ417/pdf/PLAW-109publ417.pdf (2006)
50. Suzuki, Y., Odagiri, T., Tashiro, M. & Nobusawa, E. Development of an influenza A master virus for generating high-growth reassortants for A/Anhui/1/2013(H7N9) vaccine production in qualified MDCK cells. PLoS ONE 11, e0160040 (2016)
51. US Department of Health & Human Services. A milestone in protection from influenza. http://www.hhs.gov/news/press/2014pres/06/20140617a.html (2014)
52. Seqirus. Seqirus answers the call for better and faster influenza vaccine technologies. http://www.seqirus-us.com/media-room/press-releases/Seqirus-Answers-the-Call-for-Better-and-Faster-Influenza-Vaccine-Technologies (2018)
53. Protein Sciences Corporation. Superior Protection by Flublok® Influenza Vaccine in Seniors Documented in New England Journal of Medicine [press release, online]. http://www.proteinsciences.com/PDF/pscp2.pdf(2017)